Compare VICI & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VICI | IQV |
|---|---|---|
| Founded | 2016 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Real Estate Investment Trusts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.7B | 28.6B |
| IPO Year | 2017 | 2013 |
| Metric | VICI | IQV |
|---|---|---|
| Price | $28.63 | $159.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $33.75 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 5.5M | 1.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | 1.95 | ★ 4.67 |
| EPS | 2.61 | ★ 7.84 |
| Revenue | $4,006,116,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $4.47 | $6.77 |
| Revenue Next Year | $1.67 | $5.89 |
| P/E Ratio | ★ $10.89 | $20.85 |
| Revenue Growth | 4.08 | ★ 41.60 |
| 52 Week Low | $26.55 | $134.65 |
| 52 Week High | $34.01 | $247.05 |
| Indicator | VICI | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 37.34 |
| Support Level | $27.65 | N/A |
| Resistance Level | $28.75 | $181.95 |
| Average True Range (ATR) | 0.49 | 5.77 |
| MACD | 0.07 | -1.22 |
| Stochastic Oscillator | 42.65 | 12.45 |
VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, wellness, entertainment and leisure destinations, subject to long-term triple net leases. It own nearly 93 experiential assets across a geographically portfolio consisting of nearly 54 gaming properties and nearly 39 other experiential properties across the United States and Canada, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.